BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 21262971)

  • 1. Protein-tyrosine phosphatase DEP-1 controls receptor tyrosine kinase FLT3 signaling.
    Arora D; Stopp S; Böhmer SA; Schons J; Godfrey R; Masson K; Razumovskaya E; Rönnstrand L; Tänzer S; Bauer R; Böhmer FD; Müller JP
    J Biol Chem; 2011 Apr; 286(13):10918-29. PubMed ID: 21262971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell transformation by FLT3 ITD in acute myeloid leukemia involves oxidative inactivation of the tumor suppressor protein-tyrosine phosphatase DEP-1/ PTPRJ.
    Godfrey R; Arora D; Bauer R; Stopp S; Müller JP; Heinrich T; Böhmer SA; Dagnell M; Schnetzke U; Scholl S; Östman A; Böhmer FD
    Blood; 2012 May; 119(19):4499-511. PubMed ID: 22438257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of the protein-tyrosine phosphatase DEP-1 with its substrate FLT3 visualized by in situ proximity ligation assay.
    Böhmer SA; Weibrecht I; Söderberg O; Böhmer FD
    PLoS One; 2013; 8(5):e62871. PubMed ID: 23650535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FLT3 signals via the adapter protein Grb10 and overexpression of Grb10 leads to aberrant cell proliferation in acute myeloid leukemia.
    Kazi JU; Rönnstrand L
    Mol Oncol; 2013 Jun; 7(3):402-18. PubMed ID: 23246379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NOX4-driven ROS formation mediates PTP inactivation and cell transformation in FLT3ITD-positive AML cells.
    Jayavelu AK; Müller JP; Bauer R; Böhmer SA; Lässig J; Cerny-Reiterer S; Sperr WR; Valent P; Maurer B; Moriggl R; Schröder K; Shah AM; Fischer M; Scholl S; Barth J; Oellerich T; Berg T; Serve H; Frey S; Fischer T; Heidel FH; Böhmer FD
    Leukemia; 2016 Feb; 30(2):473-83. PubMed ID: 26308771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD.
    Rocnik JL; Okabe R; Yu JC; Lee BH; Giese N; Schenkein DP; Gilliland DG
    Blood; 2006 Aug; 108(4):1339-45. PubMed ID: 16627759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia.
    Nogami A; Oshikawa G; Okada K; Fukutake S; Umezawa Y; Nagao T; Kurosu T; Miura O
    Oncotarget; 2015 Apr; 6(11):9189-205. PubMed ID: 25826077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FYN expression potentiates FLT3-ITD induced STAT5 signaling in acute myeloid leukemia.
    Chougule RA; Kazi JU; Rönnstrand L
    Oncotarget; 2016 Mar; 7(9):9964-74. PubMed ID: 26848862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The protein tyrosine phosphatase, Shp2, positively contributes to FLT3-ITD-induced hematopoietic progenitor hyperproliferation and malignant disease in vivo.
    Nabinger SC; Li XJ; Ramdas B; He Y; Zhang X; Zeng L; Richine B; Bowling JD; Fukuda S; Goenka S; Liu Z; Feng GS; Yu M; Sandusky GE; Boswell HS; Zhang ZY; Kapur R; Chan RJ
    Leukemia; 2013 Feb; 27(2):398-408. PubMed ID: 23103841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Y589 and Y599 in the juxtamembrane domain of Flt3 as ligand-induced autophosphorylation sites involved in binding of Src family kinases and the protein tyrosine phosphatase SHP2.
    Heiss E; Masson K; Sundberg C; Pedersen M; Sun J; Bengtsson S; Rönnstrand L
    Blood; 2006 Sep; 108(5):1542-50. PubMed ID: 16684964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adaptor protein Lnk binds to and inhibits normal and leukemic FLT3.
    Lin DC; Yin T; Koren-Michowitz M; Ding LW; Gueller S; Gery S; Tabayashi T; Bergholz U; Kazi JU; Rönnstrand L; Stocking C; Koeffler HP
    Blood; 2012 Oct; 120(16):3310-7. PubMed ID: 22942183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A genome-wide RNAi screen identifies proteins modulating aberrant FLT3-ITD signaling.
    Caldarelli A; Müller JP; Paskowski-Rogacz M; Herrmann K; Bauer R; Koch S; Heninger AK; Krastev D; Ding L; Kasper S; Fischer T; Brodhun M; Böhmer FD; Buchholz F
    Leukemia; 2013 Dec; 27(12):2301-10. PubMed ID: 23508117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pim2 complements Flt3 wild-type receptor in hematopoietic progenitor cell transformation.
    Agrawal S; Koschmieder S; Bäumer N; Reddy NG; Berdel WE; Müller-Tidow C; Serve H
    Leukemia; 2008 Jan; 22(1):78-86. PubMed ID: 17943165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD.
    Okamoto M; Hayakawa F; Miyata Y; Watamoto K; Emi N; Abe A; Kiyoi H; Towatari M; Naoe T
    Leukemia; 2007 Mar; 21(3):403-10. PubMed ID: 17230226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tyrosine 842 in the activation loop is required for full transformation by the oncogenic mutant FLT3-ITD.
    Kazi JU; Chougule RA; Li T; Su X; Moharram SA; Rupar K; Marhäll A; Gazi M; Sun J; Zhao H; Rönnstrand L
    Cell Mol Life Sci; 2017 Jul; 74(14):2679-2688. PubMed ID: 28271164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deficiency of core fucosylation activates cellular signaling dependent on FLT3 expression in a Ba/F3 cell system.
    Duan C; Fukuda T; Isaji T; Qi F; Yang J; Wang Y; Takahashi S; Gu J
    FASEB J; 2020 Feb; 34(2):3239-3252. PubMed ID: 31908039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukemogenic potency of the novel FLT3-N676K mutant.
    Huang K; Yang M; Pan Z; Heidel FH; Scherr M; Eder M; Fischer T; Büsche G; Welte K; von Neuhoff N; Ganser A; Li Z
    Ann Hematol; 2016 Apr; 95(5):783-91. PubMed ID: 26891877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.
    Mizuki M; Fenski R; Halfter H; Matsumura I; Schmidt R; Müller C; Grüning W; Kratz-Albers K; Serve S; Steur C; Büchner T; Kienast J; Kanakura Y; Berdel WE; Serve H
    Blood; 2000 Dec; 96(12):3907-14. PubMed ID: 11090077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation.
    Brandts CH; Sargin B; Rode M; Biermann C; Lindtner B; Schwäble J; Buerger H; Müller-Tidow C; Choudhary C; McMahon M; Berdel WE; Serve H
    Cancer Res; 2005 Nov; 65(21):9643-50. PubMed ID: 16266983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
    Spiekermann K; Bagrintseva K; Schwab R; Schmieja K; Hiddemann W
    Clin Cancer Res; 2003 Jun; 9(6):2140-50. PubMed ID: 12796379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.